Status:
COMPLETED
Comparison of SoloSTAR With a Syringe-administered Glargine Insulin in Diabetic Patients From the Hospital
Lead Sponsor:
University of Colorado, Denver
Collaborating Sponsors:
Sanofi
Conditions:
Diabetes
Eligibility:
All Genders
22-70 years
Phase:
PHASE4
Brief Summary
In this study the investigators would like to test the hypothesis that in diabetic patients discharged from the hospital, SoloSTAR Glargine insulin will be superior to syringe-injected Glargine in ter...
Eligibility Criteria
Inclusion
- All patients with type 1 and 2 diabetes discharged from the hospital with recommendations to take Glargine
Exclusion
- Patients unwilling to participate and patients incapable of complying with the study regimen, such as patients with alcohol and drug addiction problems and patients with severe mental illness
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
43 Patients enrolled
Trial Details
Trial ID
NCT01203774
Start Date
September 1 2010
End Date
August 1 2013
Last Update
August 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver
Aurora, Colorado, United States, 80045